Evaluating Secondary Findings in Prenatal Exome Sequencing: A Study of Uptake and Yield for ACMG and Childhood Onset Disorder Results

ASHG 2026

Oct 20, 2026
Hereditary
Presentation

Kayleigh Avello, Brooklynn Gross, Erica Smith, Christina Alamillo, Steven Harrison, Kelly Hagman, Kelly Radtke, Wendy Alcaraz

Introduction
In 2020, the American College of Medical Genetics and Genomics (ACMG) published a points to consider document on prenatal exome and genome testing. Recommendations included offering a new category of secondary findings (SFs) for prenatal cases: Childhood Onset Disorders (COD). While no specific gene list was provided, ACMG recommended that laboratories prioritize conditions that have high penetrance, are moderate to severe in clinical presentation and are pediatric in onset. Although several years have passed, limited data has been published on prenatal SFs. This study evaluates the uptake and incidence at a large clinical laboratory using both the standard ACMG list as well as an internally curated list of COD genes.

 

Methods
This study was a retrospective review of prenatal exomes reported at a commercial clinical lab from 2018-2026. In total, 226 prenatal cases were analyzed to determine whether ACMG and/or COD secondary findings were requested, and if any secondary findings were reported. Additionally, primary diagnostic results were reviewed to determine the prevalence of diagnostic variants within genes included on the COD list. Lastly, all pediatric and adult exome cases in this time period were also reviewed to determine if the primary result encompassed a COD gene as the molecular diagnosis to compare incidence of these rare diseases across the lifespan.

 

Results
In this study, 60% of prenatal cases (N= 135/226) opted into SFs (ACMG only: 114, Both: 21). Four cases (3%, N= 4/135) received positive SF results in genes specific to the ACMG medically actionable list; however, none of those cases yielded a primary finding that explained the clinical indication for ordering the exome. Further, no case in the total cohort received a positive SF report in a COD gene. In comparison, a primary diagnostic result within a gene on the current internal COD list was found in 8% (N= 18/226) of prenatal cases. Four additional prenatal cases had uncertain primary reports due to either a variant(s) of uncertain significance or a single pathogenic/likely pathogenic variant in a recessive gene. Across all pediatric and adult patients tested via exome at the commercial lab, 3.1% (N= 940/30,000) had a relevant variant(s) reported within a gene on the COD list.

 

Conclusions
Most patients opted in for prenatal SFs, and the overall positive rate was in line with the reported range of 2-5% for ACMG SFs. While many families selected to receive COD SFs, no positives were reported in this small cohort. Instead, most findings in genes on the COD list were reported as primary findings. This suggests that a large number of the current curated COD SF conditions have an early prenatal onset, where the phenotype can be utilized for finding a diagnostic result, or the phenotype develops after birth where the molecular cause is determined after the prenatal period. Additionally, the number of positive SF results may increase over time as the respective gene lists evolve, more uncertain variants are upgraded, and SFs are increasingly requested in the prenatal setting overall.